As the White House prepares to launch TrumpRx and advance its efforts to lower drug prices, hospital pharmacy leaders are closely watching the changes but remain cautious about how quickly they will translate into meaningful relief for patients or providers.
The administration’s strategy centers on voluntary drug pricing agreements and new purchasing pathways designed to lower medication costs, but hospital leaders say the real test will be whether those savings translate into lower out-of-pocket spending for patients. If savings do not reach patients, health systems may see little downstream relief in medication adherence and preventable care utilization that often drives uncompensated care costs.
Joseph Pinto, vice president of pharmacy operations at Mount Sinai Health System in New York City, cautioned that recent federal drug pricing initiatives may fall short of creating long-term, large-scale reductions in patients’ medication costs.
“In the near term, most drug pricing initiatives will likely produce incremental rather than systemic improvements in affordability and access,” Mr. Pinto said.
He said cost pressures often stem less from drug list prices than from insurance benefit design, rebate arrangements and utilization management policies that ultimately determine what patients pay out of pocket.
Mr. Pinto’s comments come as the Trump administration advances reforms centered on a most-favored-nation pricing model, which ties prices paid by federal programs, including Medicare and Medicaid, for certain drugs to the lowest prices paid in comparable developed countries. Since last fall, 16 of the top 17 major drugmakers have signed voluntary agreements applying the model to portions of their portfolios, including treatments for cancer, diabetes and autoimmune diseases.
Those discounted medications are expected to become available later in February through TrumpRx, a federal direct-to-consumer purchasing platform that allows patients to buy select drugs at reduced prices outside of traditional insurance channels.
At the same time, Medicare has begun implementing its first negotiated drug prices under the Inflation Reduction Act, leaving providers and policymakers watching to see whether federal savings ultimately reach patients.
“These developments signal a period of experimentation in drug pricing and distribution,” Mr. Pinto said.
If lower prices do not translate into reduced out-of-pocket costs, patients may continue to skip or delay taking medications, contributing to avoidable emergency department visits and hospitalizations that health systems often absorb as uncompensated care.
If savings materialize within Medicare or Medicaid, how those funds are used will be critical, Mr. Pinto said.
“Any realized drug savings should be reinvested in ways that directly strengthen patient care and provider effectiveness,” he said.
Mr. Pinto pointed to expanding access to high-value therapies, strengthening team-based care models that integrate pharmacists and investing in tools that help clinicians consider medication costs in real time as key reinvestment opportunities. He added that efforts should prioritize long-term outcomes rather than short-term cost reductions.
While direct-to-consumer models may improve convenience for certain therapies, they also risk fragmenting care if not integrated into provider workflows, Mr. Pinto said. Similarly, pricing reforms such as most-favored-nation models must be implemented carefully to avoid unintended disruptions to access, particularly if manufacturers respond by limiting supply or narrowing distribution of certain therapies in response to lower reimbursement rates.
Partnerships between government and industry can be effective when they remain transparent and focused on long-term sustainability for both patients and health systems, he added.
“Ultimately, the leadership challenge is balancing affordability with access, innovation with integration and cost control with clinical integrity — ensuring that policy and market shifts translate into meaningful value for patients and the healthcare workforce,” Mr. Pinto said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.